- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.08. | OnKure Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.08. | OnKure Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 26.06. | OnKure Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 28.05. | OnKure Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 06.05. | OnKure Therapeutics GAAP EPS of $1.19 | 1 | Seeking Alpha | ||
| ONKURE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 06.05. | OnKure Therapeutics, Inc. - 10-Q, Quarterly Report | 4 | SEC Filings | ||
| 06.05. | OnKure Therapeutics, Inc.: OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights | 168 | GlobeNewswire (Europe) | -- Continued progress in the PIKture-01 trial; on track to report additional data in the second half of 2025, including mature single agent and initial combination data -- Expansion of the Company's... ► Artikel lesen | |
| 06.05. | OnKure Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 30.04. | Evercore ISI starts OnKure stock with Outperform rating | 2 | Investing.com | ||
| 18.03. | H.C. Wainwright cuts OnKure Therapeutics price target to $34 | 8 | Investing.com | ||
| 10.03. | OnKure Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 10.03. | OnKure Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.03. | OnKure Therapeutics, Inc.: OnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights | 271 | GlobeNewswire (Europe) | - PIKture-01 trial update including additional PK data, mature single agent and initial combination data expected in the second half of 2025; reported encouraging preliminary data in December 2024... ► Artikel lesen | |
| 10.03. | OnKure Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 10.12.24 | OnKure Therapeutics, Inc.: OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219 | 243 | GlobeNewswire (Europe) | -- OKI-219 is well-tolerated across all doses, and no dose interruptions, delays, reductions, or discontinuations were reported -- Initial patient data show exposures of OKI-219 exceeding levels associated... ► Artikel lesen | |
| 04.10.24 | OnKure Therapeutics, Inc. Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million | 296 | GlobeNewswire (Europe) | -- OnKure is focused on advancing a pipeline of candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Ka), initially in breast cancer -- On track to announce early clinical... ► Artikel lesen | |
| 03.10.24 | Reneo Pharmaceuticals, Inc.: Reneo Pharmaceuticals Announces Stockholder Approval of Merger with OnKure | 264 | GlobeNewswire (Europe) | - Combined company to trade on Nasdaq under ticker "OKUR" - Reneo announces 1-for-10 reverse split of common stock IRVINE, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq:... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 21,025 | -0,10 % | Lohnt hier der Einstieg? NetraMark, Novartis, Pfizer | Aufgrund der globalen Nachfrage nach Gesundheitsdienstleistungen und technologischen Erneuerungen kann eine Investition in den Gesundheitssektor besonders lukrativ sein. Der demografische Wandel in... ► Artikel lesen | |
| SANOFI | 79,15 | +0,88 % | DEUTSCHE BANK RESEARCH stuft SANOFI auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat das Kursziel für die Aktien von Sanofi von 90 auf 110 Euro angehoben und die Papiere von "Hold" auf "Buy" hochgestuft. Amlitelimab könnte ein... ► Artikel lesen | |
| INNOCAN PHARMA | - | - | Innocan Pharma gibt Details zur vorgeschlagenen Aktienkonsolidierung bekannt | Herzliya, Israel und Calgary, Alberta - 29. August 2025 / IRW-Press / Innocan Pharma Corporation ("Innocan" oder das "Unternehmen") (CSE: INNO) (FWB: IP4) (OTCQB: INNPF) freut sich bekannt zu geben... ► Artikel lesen | |
| ASSEMBLY BIOSCIENCES | 19,900 | 0,00 % | Assembly Biosciences: Mega-Daten und Investoren-Ansturm | Es geht Schlag auf Schlag: Heute Morgen erst hatte ich über die neuesten, positiven Entwicklungen bei Assembly Biosciences berichtet, schon folgen die nächsten Kracher, die für ein neues Kurshoch sorgen.... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 32,400 | +4,52 % | Analysts postive on Nektar opportunity after Sanofi data | ||
| JAGUAR HEALTH | 1,640 | 0,00 % | Jaguar Health, Inc.: Jaguar Health Participating in August 25-26 Animal Health Summit with Goal of Securing Collaboration to Expand Canalevia's Indication to Treatment of General Diarrhea in Dogs | Canalevia® (crofelemer delayed-release tablets), under the name Canalevia®-CA1, is conditionally approved by the FDA for treatment of CID in dogsCompany strategy: In discussions with multiple potential... ► Artikel lesen | |
| UNITED THERAPEUTICS | 327,30 | +0,21 % | Aktien New York: Steigende US-Zinsen und schwache Techwerte belasten | NEW YORK (dpa-AFX) - Steigende Zinsen an den Kapitalmärkten und teils stark fallende Technologieaktien haben am Dienstag die großen US-Aktienindizes belastet. Der Leitindex Dow Jones Industrial fiel... ► Artikel lesen | |
| ROYALTY PHARMA | 31,630 | -0,16 % | Royalty Pharma Prices $2 Bln Offering Of Senior Unsecured Notes | WASHINGTON (dpa-AFX) - Royalty Pharma plc (RPRX) announced the pricing of a $2.0 billion offering of senior unsecured notes. The issuance includes $600 million of 4.450% Notes due 2031, $900... ► Artikel lesen | |
| BRIDGEBIO PHARMA | 44,890 | +0,90 % | BridgeBio Pharma, Inc.: Acoramidis Demonstrates Statistically Significant Reduction in Cardiovascular Mortality (CVM) through Month 42 of the ATTRibute-CM Open Label Extension | - Acoramidis demonstrated a significant reduction in risk of CVM through 42 months post-randomization, with a 44% hazard reduction, setting a new standard for CVM outcomes for patients with ATTR-CM... ► Artikel lesen | |
| CORBUS PHARMACEUTICALS | 8,450 | -2,31 % | Corbus Pharmaceuticals Holdings, Inc.: Corbus Pharmaceuticals Initiates Multiple Ascending Dose Portion of Phase 1 Study of Highly Peripherally Restricted CB1 Inverse Agonist CRB-913 for the Treatment of Obesity | No treatment-related neuropsychiatric events seen to date in SAD portion of Phase 1MAD study on track for completion in Q3 2025 NORWOOD, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals... ► Artikel lesen | |
| SOLIGENIX | 3,020 | 0,00 % | Soligenix Tumbles After Company Publishes Paper | ||
| KALA BIO | 12,670 | +2,18 % | KALA BIO, Inc.: KALA BIO Appoints Todd Bazemore as President, Chief Executive Officer and Director | ARLINGTON, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative... ► Artikel lesen | |
| MEI PHARMA | 4,270 | 0,00 % | MEI Pharma, Inc. - 8-K, Current Report | ||
| ACLARIS THERAPEUTICS | 1,793 | +0,65 % | Aclaris Therapeutics, Inc.: Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and ... | - Primary Endpoint Analysis Confirms Favorable Tolerability Profile of ATI-2138 Without Certain Risks Associated with Other Agents in the Class - - Efficacy Results Show Comparable Outcomes to Approved... ► Artikel lesen | |
| NEUROGENE | 16,620 | -1,19 % | Neurogene GAAP EPS of -$1.05 |
ONKURE THERAPEUTICS INC gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 2,680 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ONKURE THERAPEUTICS INC finden Sie auf Wallstreet Online.